Victory Capital Management Inc. Has $36.34 Million Holdings in Perrigo Company plc (NYSE:PRGO)

Victory Capital Management Inc. lessened its position in shares of Perrigo Company plc (NYSE:PRGO) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,413,338 shares of the company’s stock after selling 8,950 shares during the quarter. Victory Capital Management Inc. owned approximately 1.04% of Perrigo worth $36,337,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Versant Capital Management Inc acquired a new stake in shares of Perrigo during the 4th quarter worth approximately $45,000. GAMMA Investing LLC grew its position in shares of Perrigo by 93.7% during the 4th quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $49,000 after buying an additional 929 shares during the period. Central Pacific Bank Trust Division grew its position in shares of Perrigo by 33.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock worth $51,000 after buying an additional 500 shares during the period. Venturi Wealth Management LLC acquired a new stake in shares of Perrigo during the 3rd quarter worth approximately $56,000. Finally, KBC Group NV grew its position in shares of Perrigo by 25.1% during the 3rd quarter. KBC Group NV now owns 4,517 shares of the company’s stock worth $118,000 after buying an additional 905 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Performance

NYSE PRGO opened at $27.81 on Monday. The company has a fifty day simple moving average of $25.25 and a 200 day simple moving average of $26.23. Perrigo Company plc has a 12-month low of $23.14 and a 12-month high of $33.46. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. The company has a market cap of $3.79 billion, a P/E ratio of -23.77 and a beta of 0.48.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.01. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.20 billion. Sell-side analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Friday, March 7th will be paid a dividend of $0.29 per share. The ex-dividend date is Friday, March 7th. This is a boost from Perrigo’s previous quarterly dividend of $0.28. This represents a $1.16 annualized dividend and a yield of 4.17%. Perrigo’s dividend payout ratio (DPR) is -92.80%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PRGO. Piper Sandler downgraded shares of Perrigo from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $34.00 to $27.00 in a research report on Monday, January 6th. StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Finally, Argus downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.00.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.